Evidence map›Paper›PMID 40429739›Full record

SynthesisInternational journal of molecular sciences2025

Positivity Rate of PD-L1 Expression and Its Clinical Significance in Vulvar Cancer: A Systematic Review and Meta-Analysis.

Stefanos Flindris, Crysoula Margioula-Siarkou, Christos V Chalitsios, Georgia Margioula-Siarkou, Emmanouela-Aliki Almperi, Aristarchos Almperis, Effrosyni Styliara, Konstantinos Flindris, Minas Paschopoulos, Iordanis Navrozoglou and 4 more

Abstract readSystematic ReviewMeta-Analysis
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Stefanos Flindris2nd Department of Obstetrics and Gynecology, Aristotle University of Thessaloniki, 546 42 Thessaloniki, Greece.ORCID 0000-0002-2361-3470
Crysoula Margioula-Siarkou2nd Department of Obstetrics and Gynecology, Aristotle University of Thessaloniki, 546 42 Thessaloniki, Greece.ORCID 0000-0002-2420-4003
Christos V ChalitsiosDepartment of Hygiene and Epidemiology, University of Ioannina, 451 10 Ioannina, Greece.ORCID 0000-0002-0836-9385
Georgia Margioula-Siarkou2nd Department of Obstetrics and Gynecology, Aristotle University of Thessaloniki, 546 42 Thessaloniki, Greece.
Emmanouela-Aliki Almperi2nd Department of Obstetrics and Gynecology, Aristotle University of Thessaloniki, 546 42 Thessaloniki, Greece.ORCID 0000-0003-3502-0143
Aristarchos Almperis2nd Department of Obstetrics and Gynecology, Aristotle University of Thessaloniki, 546 42 Thessaloniki, Greece.ORCID 0000-0002-2822-2452
Effrosyni StyliaraDepartment of Radiology, University Hospital of Ioannina, 455 00 Ioannina, Greece.
Konstantinos FlindrisDepartment of Ophthalmology, General Hospital of Ioannina 'G. Hatzikosta', 454 45 Ioannina, Greece.ORCID 0009-0001-9234-5430
Minas PaschopoulosDepartment of Obstetrics and Gynecology, University Hospital of Ioannina, 455 00 Ioannina, Greece.
Iordanis NavrozoglouDepartment of Obstetrics and Gynecology, University Hospital of Ioannina, 455 00 Ioannina, Greece.
Konstantinos K TsilidisDepartment of Hygiene and Epidemiology, University of Ioannina, 451 10 Ioannina, Greece.
Konstantinos Dinas2nd Department of Obstetrics and Gynecology, Aristotle University of Thessaloniki, 546 42 Thessaloniki, Greece.ORCID 0000-0001-7144-2840
Stamatios Petousis2nd Department of Obstetrics and Gynecology, Aristotle University of Thessaloniki, 546 42 Thessaloniki, Greece.ORCID 0000-0002-5564-0406
Georgios MarkozannesDepartment of Hygiene and Epidemiology, University of Ioannina, 451 10 Ioannina, Greece.ORCID 0000-0001-8481-579X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The prevalence and prognostic value of programmed death ligand 1 (PD-L1) expression, as a potential biomarker in vulvar squamous cell carcinomas (VSCCs), remain underexplored. We searched the PubMed, Scopus, Embase, and Cochrane Library databases until July 2024 for articles examining PD-L1 expression in VSCCs. Random-effects meta-analyses summarized PD-L1 expression overall and in subgroups by immunohistochemistry antibody type, positivity cutoff, tumor stage, and HPV positivity. Additionally, random-effects meta-analyses summarized the association between PD-L1 positivity and cancer prognosis. We included 26 studies comprising 1912 VSCC cases. The summary PD-L1 positivity rate in tumor cells was 59.9% (95% confidence interval [CI]: 47.7-71.4%; I

Indexed as

B7-H1 AntigenBiomarkers, TumorCarcinoma, Squamous CellVulvar NeoplasmsClinical RelevanceFemaleHumansPrognosisB7-H1 AntigenBiomarkers, TumorCD274 protein, humandetection rateoverall survivalPD-L1positivity rateprogression-free survivalvulvar cancer

Identifiers

PMID40429739
PMCPMC12111622

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.